OncoMatch/Clinical Trials/NCT07653503
Neoadjuvant Lymph Node Targeted Immunotherapy in Cervical Cancer: a Feasibility Study (NEOLYNC)
Is NCT07653503 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies Nivolumab for cervical carcinoma.
Treatment: Nivolumab
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Cervical Cancer
Disease stage
Required: Stage < FIGO IB3
Demographics
Prior therapy
Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07653503 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage < FIGO IB3 is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages